Chemotherapy for bladder cancer in patients with impaired renal function

Nature Reviews Urology

Volumn 9, Issue 1, 2012, Pages 52-57

  Nicholson, Steve ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; PLATINUM; VINCRISTINE;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DRUG EXCRETION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; HUMANS; KIDNEY FUNCTION TESTS; NEOADJUVANT THERAPY; RENAL INSUFFICIENCY; URINARY BLADDER NEOPLASMS;

EID: 84855213858     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.176     Document Type: Review

References (54)

1. Bladder cancer - UK incidence statistics. Cancer Research UK [online], http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence (2011).
2. Dash, A. et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107, 506-513 (2006). (Pubitemid 44107210)
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, S1-S266 (2002).
4. Galsky, M. D. et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 12, 211-214 (2011).
5. Raj, G. V., Iasonos, A., Herr, H. & Donat, S. M. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J. Clin. Oncol. 24, 3095-3100 (2006). (Pubitemid 46638946)
6. Merrin, C. Treatment of advanced bladder cancer with cis- diamminedichloroplatinum (II NSC 119875): a pilot study. J. Urol. 119, 493-495 (1978). (Pubitemid 8341473)
7. Soloway, M. S. Cis-diamminedichloroplatinum II in advanced urothelial cancer. J. Urol. 120, 716-719 (1978). (Pubitemid 9091405)
8. Prestayko, A. W., Luft, F. C., Einhorn, L. & Crooke, S. T. Cisplatin pharmacokinetics in a patient with renal dysfunction. Med. Pediatr. Oncol. 5, 183-188 (1978). (Pubitemid 9169640)
9. Ribrag, V. et al. Test dose-guided administration of cisplatin in an anephric patient: a case report. Ann. Oncol. 4, 679-682 (1993). (Pubitemid 23291815)
10. Haim, N. et al. Estimation of creatinine clearance without 24-hour urine collection - a useful guide during cisplatin therapy. Acta Oncol. 32, 409-412 (1993). (Pubitemid 23268573)
11. Mead, G. M. et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br. J. Cancer 78, 1067-1075 (1998). (Pubitemid 28463984)
12. von der Maase, H. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 17, 3068-3077 (2000).
13. Carles, J. et al. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function. Clin. Transl. Oncol. 8, 755-757 (2006).
14. Hussain, S. A. et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br. J. Cancer 91, 844-849 (2004). (Pubitemid 39273773)
15. Petrioli, R. et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study. Cancer 77, 344-351 (1996).
16. Bellmunt, J. et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80, 1966-1972 (1997). (Pubitemid 27479792)
17. Bellmunt, J., de Wit, R., Albanell, J. & Baselga, J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur. J. Cancer 37, 2212-2215 (2001). (Pubitemid 33001291)
18. Carles, J. et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59, 24-27 (2000). (Pubitemid 30435831)
19. Linardou, H. et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 64, 479-484 (2004). (Pubitemid 39200741)
20. Nogué-Aliguer, M. et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract. Cancer 97, 2180-2186 (2003). (Pubitemid 36444058)
21. Shannon, C. et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann. Oncol. 12, 947-952 (2001). (Pubitemid 32725767)
22. De Santis, M. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II - results of EORTC study 30986. J. Clin. Oncol. 27, 5634-5639 (2009).
23. Dogliotti, L. et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur. Urol. 52, 134-141 (2007). (Pubitemid 46803003)
24. Galsky, M. D. et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdr156
25. Dreicer, R. et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100, 1639-1645 (2004). (Pubitemid 38456340)
26. Calvert, A. H. & Egorin, M. J. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur. J. Cancer 38, 11-16 (2002). (Pubitemid 34031819)
27. Roth, B. et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 12, 2264-2270 (1994). (Pubitemid 24346693)
28. Dimopoulos, M. A. et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 52, 56-60 (1998). (Pubitemid 28317930)
29. Vaughn, D. J. et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 16, 255-260 (1998). (Pubitemid 28041606)
30. Friedland, D. M., Dakhil, S., Hollen, C., Gregurich, M. A. & Asmar, L. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer. Cancer Invest. 22, 374-382 (2004). (Pubitemid 39310907)
31. Johannsen, M. et al. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. Eur. Urol. 48, 246-251 (2005). (Pubitemid 40957098)
32. Kouno, T. et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur. Urol. 52, 1115-1122 (2007). (Pubitemid 47332041)
33. Fechner, G. et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int. J. Clin. Pract. 60, 27-31 (2006). (Pubitemid 43732573)
34. Matsumoto, K. et al. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int. J. Urol. 14, 1000-1004 (2007). (Pubitemid 47621839)
35. Suyama, T. et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J. Clin. Oncol. 39, 244-250 (2009).
36. Hussain, M., Vaishampayan, U., Du, W., Redman, B. & Smith, D. C. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 19, 2527-2533 (2001). (Pubitemid 32391224)
37. Pectasides, D. et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann. Oncol. 13, 243-250 (2002). (Pubitemid 34704976)
38. Galsky, M. D. et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109, 549-555 (2007). (Pubitemid 46190963)
39. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202-205 (2005).
40. Winquist, E. et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol. 171, 561-569 (2004). (Pubitemid 38090430)
41. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 48, 189-199 (2005).
42. Ghoneim, M. A., el-Mekresh, M. M., el-Baz, M. A., el-Attar, I. A. & Ashamallah, A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J. Urol. 158, 393-399 (1997). (Pubitemid 27327674)
43. Galsky, M. D. et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 69, 255-259 (2007). (Pubitemid 46274943)
44. Swanson, D. A., Liles, A. & Zagars, G. K. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J. Urol. 143, 37-40 (1990). (Pubitemid 20020366)
45. Serretta, V., Pomara, G., Piazza, F. & Gange, E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur. Urol. 37, 85-89 (2000). (Pubitemid 30072380)
46. Richie, J. P., Waisman, J., Skinner, D. G. & Dretler, S. P. Squamous carcinoma of the bladder: treatment by radical cystectomy. J. Urol. 115, 670-672 (1976).
47. Rundle, J. S. et al. Squamous cell carcinoma of bladder. A review of 114 patients. Br. J. Urol. 54, 522-526 (1982). (Pubitemid 13204329)
48. Choong, N., Quevedo, J. & Kaur, J. Small cell carcinoma of the urinary bladder. Cancer 103, 1172-1178 (2005).
49. Kaya, A. O. et al. Primary pure small cell carcinoma of the urinary bladder that responded to carboplatin plus etoposide: a case report and review of the literature. J. BUON 14, 703-706 (2009).
50. Bex, A. et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 65, 295-299 (2005). (Pubitemid 40248016)
51. Mukesh, M., Cook, N., Hollingdale, A. E., Ainsworth, N. L. & Russell, S. G. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int. 103, 747-752 (2009).
52. Tran, B. & McKendrick, J. Metastatic urachal cancer responding to FOLFOX chemotherapy. Can. J. Urol. 17, 5120-5123 (2010).
53. Mohile, S. G., Schleicher, L. & Petrylak, D. P. Treatment of metastatic urachal carcinoma in an elderly woman. Nat. Clin. Pract. Oncol. 5, 55-58 (2008). (Pubitemid 351512429)
54. Logothetis, C. J., Samuels, M. L. & Ogden, S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology 26, 252-255 (1985). (Pubitemid 17045603)